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Cardiovascular disease (CVD) is the most common cause of
death in industrialized nations. Type 2 diabetes is a CVD risk
factor that confers risk similar to a previous myocardial
infarction in an individual who does not have diabetes. In
addition, the most common cause of chronic kidney disease
(CKD) is diabetes. Together, diabetes and hypertension
account for more than two-thirds of CVD risk, and other risk
factors such as dyslipidemia contribute to the remainder of
CVD risk. CKD, particularly with presence of significant
albuminuria, should be considered an additional
cardiovascular risk factor. There is no consensus on how to
assess and stratify risk for patients with kidney disease across
subspecialties that commonly treat such patients. This paper
summarizes the results of a consensus conference utilizing a
patient case to discuss the integrated management of
hypertension, kidney disease, dyslipidemia, diabetes, and
heart failure across disciplines.
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ILLUSTRATIVE CASE
This 58-year-old non-smoking obese man presents 1 week
after hospital discharge for the treatment of heart failure.
Hospital stay revealed left ventricular hypertrophy, diastolic
dysfunction, with left ventricular systolic ejection fraction of
50% by echocardiogram, and no evidence of myocardial
ischemia. He feels well. The past medical history includes
type 2 diabetes, hypertension, and dyslipidemia treated with
ramipril 5mg, furosemide 40mg, metoprolol XL 25mg,
metformin 1 g, and atorvastatin 20mg (all daily). Physical
exam: blood pressure (BP) 152/92mm Hg, P 68/min and
regular, and body mass index 33. Jugular venous pressure is
not visible. Heart rate is regular with S1 and S2 and no
gallop. Lung exam reveals bibasilar rales. There is þ 1
peripheral edema. Data are shown in Table 1. Screening
results for anemia, and mineral and bone disorder are
unremarkable (data not shown).
BP TARGETS AND VASCULAR INJURY IN CHRONIC KIDNEY
DISEASE (CKD)
Outcomes cardiovascular and kidney disease progression
BP values 4140/90mmHg are associated with higher risk
for adverse kidney and cardiovascular outcomes.1 The
National Kidney Foundation (NKF) Kidney Disease Out-
comes Quality Initiative (KDOQI) hypertension guideline
level of evidence is A: angiotensin converting enzyme
inhibitor (ACEi) or angiotensin receptor blocker (ARB) for
proteinuric individuals, B: target o130/80, and C: protei-
nuria attenuation as a goal of therapy.2 The optimal lower BP
target is not clearly established as the trial evidence is limited
by the failure of most studies to achieveo130/80 for patients
with diabetes and/or CKD, as recommended by Joint
National Committee 7,1 American Diabetes Association,3
and KDOQI guidelines,2 for slowing the loss of kidney
function and improving cardiovascular disease (CVD) out-
comes. However, most of the studies showed that the
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achieved systolic BP (SBP) target predicts loss of kidney
function. In addition, for patients over the age of 50, the SBP is
the best predictor of myocardial infarction, heart failure, and
stroke. Lastly, the target ofo130/80 does not address the risks
of overtreatment. A meta-analysis of 61 observational studies,
including one million adults with no pre-existing CVD, did
demonstrate that risk for cardiovascular events doubles for
every systolic/diastolic 20/10 above a BP of 115/75.4 However,
in two prospective studies that randomized subjects without
diabetes to different levels of BP reduction, the African
American Study of Kidney Disease (AASK)5 and the Ramipril
Efficacy in Nephropathy-2 (REIN-2) study,6 neither kidney
disease progression nor CVD risk was reduced at the lower
target (mean arterial pressure p92 in AASK and o130/80 in
REIN-2). The Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study showed no effect of an intensive
target SBP o120 versus SBP o140 on CVD outcomes.7
A practical approach targets a sitting SBP of 130 or less if
tolerated, including assessment of symptoms of orthostatic
hypotension. In addition, current evidence supporting albu-
minuria as a therapeutic target is reviewed in detail elsewhere.8
Methods of monitoring BP are described in Table 2.9–13
Drug therapy in CKD
The diagnosis of CKD should influence the selection and
sequence of antihypertensive agent use.1,2 By the time
individuals develop impaired kidney function, three or more
drugs are generally needed to achieve BP targets. Overall,
attaining BP targets receives less attention in the literature and
is arguably more important than selection of individual agents.
Renin–angiotensin–aldosterone system (RAAS) blockade
Studies in diabetic nephropathy demonstrate that the greater
the initial decrease of kidney function with RAAS blockade,
the greater the long-term preservation of kidney function.14
Consequently, an initial limited loss of estimated glomerular
filtration rate (eGFR) following the initiation of RAAS
blockade is not a concern unless it exceeds 30–50%, in which
case states predisposing to excessive eGFR responses to RAAS
blockade such as diuretic-induced hypovolemia or renal
artery stenosis should be considered.2,15,16 If these conditions
are not present, RAAS blockade should be continued. In
addition to concern about the initial decrease of eGFR after
RAAS blockade, another common misconception is the
notion that RAAS blockade should be avoided if kidney
function is impaired. Nevertheless, when initiating RAAS
blockade, the clinician and the patient should be aware of
potential side effects associated with this therapy, e.g.,
hyperkalemia, cough, angioedema, and anemia. Because of
the association between increases in albuminuria and CKD
Table 1 | 58-Year-old non-smoking obese man with heart failure in the setting of type 2 diabetes, hypertension with preserved
left ventricular function, and dyslipidemia
Vignette data Discharge Week 1 Week 3 Week 5
Blood pressure 138/88 152/92 138/86 134/84
eGFR (ml/min per 1.73 m2) 45 43 40 34
Fasting serum test
Creatinine (mg/dl) 1.6 1.6 1.7 2.0
Potassium (mEq/l) 3.8 5.0 3.8 4.1
Cholesterol (mg/dl) 188
HDL (mg/dl) 32
LDL (mg/dl) 112
Triglycerides (mg/dl) 220
Glucose (mg/dl) 188 120 136 120
Hemoglobin A1c (%) 6.7
Urinary test
Albumin–creatinine ratio
(mg/g)
480 360 300
Intervention
Prescribed treatment Ramipril 5 mg, furosemide
40 mg, metoprolol XL 25 mg,
metformin XL 1 g,
atorvastatin 20 mg
(all once daily)
Increase furosemide
40 mg twice daily
Increase ramipril 10 mg,
substitute glipizide 10 mg
for metformin
(all once daily)
Add spironolactone
25 mg once daily
Abbreviations: eGFR, estimated glomerular filtration rate; HDL, high-density cholesterol; LDL, low-density cholesterol.
Table 2 |Methods of blood pressure measurement
Method Advantages Disadvantages
Office/clinical
blood pressure
measurement
Most commonly used in RCTs
and long-term outcome trials
Highly variable,
observer bias,
white-coat HTN
HBPM Improves patient compliance
and hypertension control rates
Requires training
and device
calibration
Detection of white-coat and
masked HTN
Wide availability and low cost
ABPM Only way to assess non-dipping
(common in CKD)
Not commonly
reimbursed by all
health insurers
Detection of white-coat and
masked HTN
Availability
Abbreviations: ABPM, ambulatory blood pressure monitoring; CKD, chronic kidney
disease; HBPM, self-home blood pressure monitoring; HTN, hypertension; RCTs,
randomized controlled trials.
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progression,17 it is important to monitor albuminuria before
and after onset of RAAS blockade to achieve optimal
attenuation. High-sodium intake further exacerbates
pre-existing albuminuria and increases CKD progression.18
If urinary albumin–creatinine ratio is not decreased by at least
430% below initial levels where treatment was initiated or to
o300mg/g, in spite of BP levelso130/80 on a low-sodium diet,
consideration should be given to addition of either a different
class of RAAS blocker or possibly diltiazem.19–21
The evidence for the combination RAAS blocking therapy
for proteinuria reduction is currently limited to a meta-
analysis of 49 small, variable quality studies wherein
proteinuria reduction was assessed against a dihydropyridine
calcium channel blocker, thus, favoring the ACEi and ARB.22
The renal outcomes with telmisartan, ramipril, or both in
people at high vascular risk (ONTARGET) study demon-
strated no benefit of the ACEi/ARB combination arm versus
either the ramipril 10mg daily or telmisartan 80mg daily
groups on initiation of chronic dialysis.23 In contrast, the
combination did significantly lower proteinuria versus either
form of monotherapy. An important caveat is that the
majority of the patients enrolled in the trial did not have
albumin–creatinine ratio X300mg/g.24
Although the potassium sparing diuretics, spironolactone,
and epleronone have been shown to reduce proteinuria, there
are no kidney outcome data,25 and their addition to ACEi or
ARB increases the risk of hyperkalemia. This hyperkalemia
risk is predominantly seen, however, among those with an
eGFRo45ml/min per 1.73m2 along with a baseline potassium
of 44.5mEq/l when already on an appropriate diuretic and
maximal dose RAAS blocker.26 Thus, the role of these agents is
not established. In addition, the direct renin inhibitor, aliskiren,
reduced proteinuria in one recent trial when added to an
ARB.27 Similarly, its role is not established. In non-proteinuric
patients, there is little definite evidence for the superiority
of the RAAS blockade over other antihypertensive medications,
except in the AASK trial, and in light of the ONTARGET trial,
combination ACEi/ARB therapy should be avoided in patients
with albumin–creatinine ratio o300mg/g.
Failure to attain BP target
If BP remains uncontrolled on three or more drugs given
in maximally effective and tolerated doses, the patient should
be referred to a hypertension specialist or nephrologist.
The main causes are insufficient diuretic treatment or failure
to restrict excessive sodium intake, non-adherence to
medications, or other medications such as nonsteroidal
anti-inflammatory drugs-induced sodium retention, and
obstructive sleep apnea.1 Table 1 describes the patient’s
course and drug interventions received.
THE IMPACT OF DYSLIPIDEMIA MANAGEMENT ON
ATHEROSCLEROSIS PROGRESSION IN CKD
Introduction
Most patients with diabetes and CKD have dyslipidemia and
are at particularly high risk for macrovascular complications,
especially in the presence of albuminuria.28,29 As eGFR
declines, high-density cholesterol falls, and some data suggest
association of dyslipidemia with more rapid loss of kidney
function. Current guidelines recommend statin therapy for
low-density cholesterol (LDL) 4100mg/dl together with
therapeutic lifestyle changes.28–30 Patients with diabetes and
CKD typically have low high-density cholesterol, hypertri-
glyceridemia, and average LDL; LDL particles in people with
diabetes tend to be smaller, denser, and possibly more
atherogenic.31–35 Therefore, CKD patients are high priority
candidates for treatment of dyslipidemia. Modifying CVD
risk by using lipid-lowering agents is a cost-effective strategy
in people with type 2 diabetes.36
LDL-lowering therapy and risk of CVD in diabetes and CKD
stages 1 to 3
Primary and secondary prevention trials, including those in
people with diabetes evaluating different statins, have
documented substantial cardiovascular benefit.37,38 The
recent primary prevention Collaborative Atorvastatin Dia-
betes Study reported an impressive decrease in cardiovascular
deaths in people with type 2 diabetes in the absence of
markedly decreased kidney function.39 In terms of absolute
risk reduction, patients in the Heart Protection Study with
diabetes and CVD received the greatest benefit from statin
therapy.40
A post hoc analysis of data from the Pravastatin Pooling
Project, a subject-level database combining results from three
randomized trials of pravastatin, 40mg daily, versus placebo,
included 19,737 subjects, of whom 4099 (20.8%) had CKD,
but not diabetes, at baseline; 873 (4.4%) had diabetes, but
not CKD; and 571 (2.9%) had both conditions.41 The
incidence of the primary composite CVD outcome was
lowest in individuals with neither CKD nor diabetes (15.2%),
intermediate in subjects with only CKD (18.6%) or only
diabetes (21.3%), and highest in subjects with both comorbid
conditions (27.0%). Pravastatin significantly reduced the risk
of the primary outcome by 25% in subjects with CKD and
comorbid diabetes and by 24% in subjects with either
characteristic. The absolute reduction in risk of the primary
outcome because of pravastatin use was highest in subjects
with both CKD and diabetes (6.4%) and lowest in subjects
with neither characteristic (3.5%). This study provides
indirect evidence that pravastatin treatment effectively
decreases the risk of CVD in diabetes with CKD stages 1 to
3. The Treating to New Targets study investigated the effects
of intensive lipid-lowering with atorvastatin 80 versus 10mg
daily in B10,000 patients (15% diabetes) with coronary
heart disease with and without pre-existing CKD for a
median follow-up of 5 years.42,43 CKD was defined solely on
the basis of eGFR o60ml/min per 1.73m2 in 3107 patients.
The patients with CKD randomized to 80mg atorvastatin
daily experienced 32% fewer cardiovascular events (hazard
ratio (HR)¼ 0.68; 95% confidence interval (CI): 0.55–0.84;
P¼ 0.0003) compared with those with CKD treated with the
10mg daily dose.43 In addition, a secondary analysis of
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3267 patients with stage 3 CKD predominantly who were
randomized to rosuvastatin 20mg daily or placebo in the
JUPITER (Justification for the Use of Statins in Prevention-
an Intervention Trial Evaluating Rosuvastatin) trial revealed
45% reduction in risk of the composite CVD outcome
(HR: 0.55, 95% CI: 0.38–0.82, P¼ 0.002) and a 44%
reduction in all-cause mortality (HR: 0.56, 95% CI:
0.37–0.85, P¼ 0.005).44 The high CVD risk associated with
diabetes and CKD stages 1 to 3 supports initiation of statin
therapy when LDL is 4100mg/dl, with the achievement of
an LDL goal of o70mg/dl as a therapeutic option.
Initiation of statin treatment in patients with CKD stage 5
on hemodialysis (CKD 5D) treatment does not improve
cardiovascular outcomes
More definite negative evidence in patients with CKD stage 5,
at least in hemodialysis patients, comes from two randomized
prospective placebo controlled trials, the German 4D
(Die Deutsche Diabetes Dialyse) study in type-2 diabetes
and the international AURORA trial.45,46 In 4D, 1255
hemodialysis patients in Germany with type-2 diabetes were
randomized to receive atorvastatin 20mg/day or placebo,
whereas in AURORA therapy was rosuvastatin 10mg daily
versus placebo for 2766 international patients of which
approximately one quarter had diabetes. Although both
studies demonstrated just over 40% LDL reduction in the
intervention groups, there was no significant difference in the
cumulative incidence of the primary composite CVD
endpoint over an average observation period of 4.0 years in
4D and 3.2 years in AURORA.
These data do not support initiation of a statin for dialysis
patients without CVD. However, patients in whom statin
therapy was initiated earlier in the course of CKD and those
who develop cardiovascular indications should be treated
with statin therapy.29
Dyslipidemia may increase albuminuria and accelerate
progression of diabetes and CKD
A number of observational studies report dyslipidemia to be
associated with decreased kidney function in the general
population and in patients with CKD, regardless of diabetes
presence.28 In the RENAAL Study, the unadjusted RR for the
primary composite end point (doubling of serum Cr, end-
stage renal disease, or death) among patients in the upper
quartile of the distribution for total cholesterol and LDL was
significantly higher than for those in the lower quartile.47
Small short-term randomized studies report mixed results of
the effect of statins on progression of diabetes in CKD. In
patients with type 1 diabetes and microalbuminuria,
simvastatin had no beneficial effect on either albuminuria
or kidney function.48 However, some randomized trials in
type 2 diabetes reported beneficial effects of statins on
albuminuria and kidney function relative to pre-treatment
levels,49–52 but not relative to placebo or an alternative class of
treatment for dyslipidemia.53,54 Whether dyslipidemia causes
reduced kidney function, or results from reduced kidney
function, or whether other conditions, such as proteinuria,
cause both reduced kidney function and dyslipidemia cannot
be determined from the available data, see Figure 1.
Statin myopathy
Statin myopathy encompasses a spectrum from relatively mild
myalgias to more severe myositis and rare rhabdomyolysis.55
Although myalgias may occur in up to 10% of patients, the
important clinical relevance is self-discontinuation of statin
therapy.55 Current literature suggests that statins are generally
safe in patients with impaired kidney function.28,29,43,44,56
However, treatment of kidney transplant recipients or
glomerular disease patients concomitantly with calcineurin
inhibitors and statins with similar P450 34A metabolism may
increase risk of myopathy, particularly when combined with a
fibrate.28 Routine monitoring of liver and muscle enzymes is
not supported by randomized trials in patients with CKD.29,56
Other agents
Dose adjustments for fibric acid derivatives in CKD are
recommended for fenofibrate, but not gemfibrozil.28 The
safety and efficacy of ezetimibe is supported by trial data in a
patients with moderate CKD.57 Bile acid sequesterants are
safe for all levels of kidney function, but should be avoided
for those with hypertriglyceridemia.
Limitations
There are no prospective randomized controlled trials
available in diabetes and CKD stages 1 to 3. Recommenda-
tions made for patients are based on post hoc analysis with
limited numbers of patients. The current recommendations
need validation in people with diabetes and stage 4 CKD. The
ongoing Study of Heart and Renal Protection, a randomized
controlled trial of simvastatin 20mgþ ezetimibe 10mg
versus placebo daily in 6000 CKD and 3000 hemodialysis
patients, may provide additional insights.58 The discussion
has primarily focused on LDL-lowering therapies (Figure 1),
but in addition the potential pleotropic effects of statins,
including their actions to attenuate oxidative stress, and
improve endothelial function may also have a therapeutic
Stage 1 Stage 5/dialysis
Increasing prevalence of CVD risk factors
Increasing risk of CVD
Increasing risk of CKD progression
4D, Aurora & SHARP analyses in 2012
BUT still need trials and experimental
data to address:
Treat dyslipidemias up to stage 3
and renal transplant patients
-  Low HDL
-  TG-rich lipoproteins
-  In both stage 3,4 and dialysis patients
   for CVD and CKD prevention
-  What are the targets?
Figure 1 |Clinical equipoise on treating dyslipidemias in CKD.
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role. Case application is summarized in the Table 1. Data
from the ACCORD lipid trial suggest that the routine
addition of a fibrate to statin therapy for individuals with
type-2 diabetes may not reduce the incidence of CVD
events.59 A recent consensus statement from the American
College of Cardiology and ADA recommends measurement
of a marker of the total burden of atherogenic particles,
ApoB, and treatment to an ApoB, or a non-high-density
cholesterol target for statin-treated patients at high risk, such
as the patient described in the case.35
IMPACT OF GLYCEMIC CONTROL ON VASCULAR INJURY
IN CKD
Introduction
Patients with diabetes are well recognized to be at increased
risk for CVD,60,61 particularly those with CKD.29,62 Clinical
practice guidelines on management of hyperglycemia in CKD
have been derived from investigations in type 1 and 2
diabetes in stages 1 and 2 (increased amounts of albuminur-
ia/proteinuria with eGFR 460ml/min per 1.73m2).29 There
is little clinical evidence derived from investigations of
patients with eGFR o60ml/min per 1.73m2, or end-stage
renal disease. Specifically, in CKD stages 3–5, there are only
limited data from intervention studies regarding optimal
HbA1c management. Further, there is minimal and con-
troversial evidence addressing the impact of HbA1c reduction
and CVD outcomes among patients with diabetes, in general.
Glycemic control and diabetes complications
Tight glycemic control in patients with both type 1 and type
2 diabetes reduces the risk of developing microvascular
(CKD, retinopathy, neuropathy) complications, including
incident microalbuminuria as well as macroalbuminuria
based on randomized controlled trials such as the Diabetes
Control and Complications Trial (DCCT/epidemiology of
diabetes interventions and complications)63 and the United
Kingdom Prospective Diabetes Study (UKPDS)64,65 the
Kumamoto Study66 and the Action in Diabetes and Vascular
Disease: Preterex and Diamicron Modified Release Contolled
Evaluation (ADVANCE) study.67 The microvascular data
from ACCORD are yet to be published. These results support
maintaining HbA1c concentrations as close to 7% as safely
possible to prevent CKD characterized by albuminuria,
consistent with guideline recommendations.3,29
Only Observational studies suggest that tighter glycemic
control is associated with a reduced risk of kidney disease
progression or onset of end-stage renal disease.68–71 However,
there is a lack of long-term trial data demonstrating that rate
of progression can be influenced by tight glycemic control at
later stages of CKD. Nevertheless, CKD progression is not the
only criterion for keeping HbA1c levels near normal. Data
supporting intensive glycemic control for preventing or
decreasing other microvascular complications of diabetes,
such as retinopathy, are strong.72
The effect of tight glycemic control on macrovascular
disease remains unclear, whether or not diabetes is complicated
by kidney disease. Data from the DCCT/EDIC Study suggest
that risk of cardiovascular events is reduced with intensive
insulin therapy and that this risk reduction is partly mediated
by prevention of CKD.73 Yet, other studies have not consistently
shown a protective effect for tight glycemic control with
regard to macrovascular complications. Recent data from the
ACCORD study suggest that intensive glycemic control
(HbA1c o6.0%) to prevent CVD results in excess mortality
in type 2 diabetic patients at high risk for heart disease,74
although this was not corroborated by the similarly designed
ADVANCE study.67 Therefore, consensus guidelines recom-
mend an HbA1c level o7% to prevent CVD complications in
the diabetes population with or without CKD.3,29
Monitoring of glycemia in CKD
Individuals with CKD stages 1 and 2 have preserved kidney
function and albuminuria. In these earlier stages, no changes
from usual diabetes care are typically required for management
of hyperglycemia or monitoring blood glucose. However,
patients with eGFR o60ml/min per 1.73m2 often display
comorbid complications contributing to advanced kidney
disease including: poor BP control, mineral and bone disorders,
malnutrition, and anemia due to decreases in erythropoietin
production. In individuals with stages 3 to 5 CKD, these
comorbidities contribute to impaired glucose metabolism and
pharmacokinetics, which render these subjects at increased risk
for hyperglycemia and hypoglycemia. Thus, it is imperative to
monitor glycemia closely and adjust doses of medications
appropriately to the level of eGFR. Although there are scant
data regarding glucose monitoring in CKD, ADA guidelines
should generally be followed.3,29
Management of glycemia in CKD
The major risk in all diabetic patients to attain HbA1c
o7.0% is hypoglycemia, particularly for those treated with
insulin, although the risk is lower in type 2 individuals.64,75
The UKPDS also showed that sulfonylureas are associated
with a small risk of hypoglycemia.64 The KDOQI guidelines
for Diabetes and CKD provide extensive recommendations
for dosing of drugs used to treat hyperglycemia in patients
with CKD stages 3 to 5, and detailed management strategies
are beyond the scope of this paper.29
Nutrition in diabetic kidney disease
Obesity. Treatment of obesity in CKD should be directed at
achieving weight loss, using exercise in the clinical context and
a diet low in calories, fat, and sodium. In small observational
studies, weight loss reduces proteinuria,76,77 and stabilizes
progression of CKD.78–81 Recent evidence suggests that in
morbidly obese subjects who fail to lose weight with traditional
measures and develop complications of increased body mass
index, bariatric surgery may be considered.74,75
Protein intake
A dietary protein intake of 0.8 g/kg body weight (about
10–15% of total calories), the recommended daily allowance
730 Kidney International (2010) 78, 726–736
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for this macronutrient, is a level that has been targeted
in nutritional intervention studies for stable outpatients
with diabetes and stages 1 to 4 CKD.29 Nutrition
surveys indicate that most Americans eat in excess of
the recommended daily allowance level.82 In two separate
meta-analyses, low-protein diets reduced risks of progression
of albuminuria/proteinuria and loss of GFR. The bene-
fits were more pronounced in diabetics with CKD.83,84
More recently, even a modest limitation of dietary protein
(0.89 g/kg body weight/day versus 1.02 g/kg body weight/day)
reduced risk of CKD stage 5 or death (RR 0.23, 95% CI:
0.07–0.72, P¼ 0.04) in persons with type 1 diabetes and stage
2 CKD.85 Benefits of limiting dietary protein intake are more
evident in type 1 than in type 2 diabetes, but fewer studies
have been done in the latter population. Based on the
available evidence, the KDOQI guidelines recommend limit-
ing the dietary protein to the recommended daily allowance
level of 0.8 g/kg body weight for CKD stages 1 to 4 to stabilize
or reduce albuminuria, slow decline in GFR, and possibly
prevent CKD progression.29
At the other end of the spectrum, high-protein diets are a
special concern in diabetes because they may increase
albuminuria and accelerate loss of kidney function.29 Higher
protein intake appears to increase glomerular hyperfiltration
and kidney damage in diabetes.86–89 Emerging epidemiologic
evidence indicates that higher protein intake (X20 versus
10% of total daily calories) is associated with loss of kidney
function in women with mildly decreased GFR (CKD stages
1–2 inferred) and development of microalbuminuria in
people with diabetes and hypertension.88,89 Therefore,
diabetic persons with CKD should avoid high-protein diets
(X20% of total daily calories).29
Sodium intake
The recommendation for daily sodium intake in the general
population is 2400mg, and even a more stringento1500mg
for nearly 70% of the US adult population, (African
Americans, hypertension, or middle to advanced age).90
Several randomized trials have demonstrated improvements
in BP with dietary sodium restriction,91–94 with associated
reductions in CVD end points.87,88 Patients with CKD are
generally less able to excrete a sodium load, making the
potential benefit even greater, although there are scant data.
Limitations
There are insufficient data to recommend any changes in
guideline recommendations of HgbA1c o7.0% in CKD at
any stage. It is also important to recognize that management
of diabetes will change based on the level of kidney function,
especially at advanced stages of CKD (e.g., GFRo60ml/min
per 1.73m2), with particular attention paid to selection of
medications regarding their side effects. Obesity is an
emerging area of interest in the management of CKD and
diabetes. Therapeutic lifestyle changes such as adjusting
protein intake and weight reduction should be emphasized in
the CKD population.
Case application
The case application in Table 1 shows glipizide 10mg
daily substitution for metformin in accordance with the
Food and Drug Administration contraindication for
serum creatinine 1.5mg/dl or greater in men (1.4 or greater
in women) for the risk of lactic acidosis.95 This is not
based on data but rather extrapolation from phenformin use.
Some clinical studies have found this risk for lactic acidosis
linked better to eGFR versus serum creatinine and suggest
that risk increases at eGFR o30ml/min per 1.73m2.96,97
If there was a concern about the hypoglycemia risk with
sulfonylureas, an alternative intervention is the use of short
acting repaglinide 1mg with meals instead of the biguanide.
Additionally, other agents such as reduced doses of
sitaglipitin at doses adjusted for level of kidney function
can be used in such patients in combination with other oral
medications.
Group IV-heart failure: consequence of and influence
on CKD
Most of the estimated five million heart failure patients in the
United States are older adults,98 with over one million
hospitalizations and over 300,000 deaths due to heart failure
annually occurring in patients who are 65 years and older.
The average age of dialysis initiation is 68 years. Heart failure
is the most common cause of death in stage 5 CKD and in
many cases is prevalent before the initiation of dialysis.
Currently, over half of the annual cost of heart failure care of
an estimated 30 billion dollars is spent for inpatient care of
heart failure.98 Heart failure is commonly associated with
coronary artery disease, hypertension, diabetes, and CKD. A
study of 105,388 heart failure patients in the Acute
Decompensated Heart Failure National Registry (ADHERE)
reported that 57% of these patients had coronary artery
disease.99
Epidemiology of CKD in heart failure
Unlike the general population, the epidemiology of CKD in
heart failure is not very well studied. Patients with high
serum Cr levels are often excluded from randomized clinical
trials in heart failure.100 Data on the prevalence of CKD in
heart failure are derived, therefore, at best, from large heart
failure registries involving hospitalized acute heart failure
patients. A study of acute hospitalized heart failure patients
from the ADHERE registry of 75,382 (64%) patients with
impaired kidney function, showed that 51,553 (44%), 15,553
(13%), and 8276 patients (7%), respectively, had stages 3, 4,
or 5 CKD.101
Risk factors for CKD in heart failure
Prospective epidemiological data on risk factors for CKD are
scarce, and most associations are derived from cross-sectional
studies. Cross-sectional data from the NHANES survey
suggest that in the general population, age, ethnicity,
education, diabetes, hypertension, CVD, and body mass
index are associated with CKD.102,103
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Data from the ADHERE registry indicate that age, sex, and
ethnicity are associated with CKD.101 However, these
associations were unique among stage 5 CKD patients, of
whom about 68% were receiving chronic dialysis. Most heart
failure patients with CKD were women (54, 58, and 54%,
respectively, for stage 3, 4, and 5), whereas most with stage 1
and 2 kidney function were men (57 and 53%, respectively).
The proportion of heart failure patients who are African
Americans with stages 1 to 5 CKD were similar across all
stages ranging from 39% in stage 1 to 33% in stage 5.101 This
suggests that these patients were more likely to develop heart
failure regardless of CKD stage. However, a separate analysis
also showed that once CKD developed, African Americans
were more likely to progress to stage 5 CKD, often requiring
chronic dialysis.104
In the Reasons for Geographic and Racial Differences in
Stroke registry, the prevalence of stage 3 or higher CKD was
higher among Whites (50 versus 34% for African Americans);
however, the prevalence of stage 4 and 5 CKD was higher
among African Americans (0.3 versus 0.1% for Whites).105
In the ADHERE registry, however, the prevalence of
systolic heart failure (ejection fractiono40%) was the lowest
among patients with stage 5 CKD (45%, stage 5 versus 53%,
stage 1).101 This suggests that either fewer patients with
systolic heart failure progress to stage 5 CKD, or heart failure
patients with low ejection fraction and stage 5 CKD receiving
dialysis had disproportionately high mortality rates. This
latter interpretation is supported by data from the United
States Renal Data System, noting a 19% per annum mortality
rate in dialysis patients, with heart failure as the most
common etiology.104
CKD as a risk factor for heart failure
Because heart failure and CKD share common risk factors
and often coexist, it may be at times difficult to determine if
CKD in heart failure is a case of prevalent or incident CKD,
or a manifestation of the cardio-renal syndrome.106–110 Data
from the Cardiovascular Health Study indicate that among
older adults, increasing baseline serum creatinine was
associated with a graded increase in the risk for incident
heart failure.111,112 A further analysis of the Cardiovascular
Health Study suggests that among older adults with no
baseline CKD, presence of CKD identified by cystatin C level
was associated with increased risk of heart failure.112 CKD
has a poor prognosis among African Americans; however,
little is known about racial variations in the CKD-associated
risk of heart failure.
In summary, CKD is associated with increased morbidity
and mortality from heart failure. CKD is also associated with
underuse of ACEi or ARB as part of a therapeutic regimen to
achieve BP goals in these patients. Increases in serum Cr are
common following administration of RAAS blockers in heart
failure patients. The physiology of why this occurs is beyond
the scope of this paper but the readers are referred to recent,
in-depth reviews.107,108,113–115 Despite concerns of acute rises
in serum Cr of up to 30%, use of these drugs has been
documented to improve cardiovascular and renal out-
comes.2,15,16 Clinicians should routinely risk stratify heart
failure patients by the presence of CKD based on eGFR values
and take preventive and therapeutic measures based on
current guidelines and appropriate nephrology consultation.
Approaches to further optimize this patient’s cardiac
function, reduce cardiovascular risk, and help normalize
albuminuria would be the addition of an aldosterone
antagonist such as spironolactone. Aldosterone antagonists
are known to reduce mortality in heart failure patients.116,117
These agents are also known to reduce proteinuria, in an
additive fashion when used with other RAAS blockers.25 The
concern about these agents is risk for hyperkalemia, however,
recent studies show that the highest risk is among patients
already on diuretics with RAAS and have a GFRo45ml/min
and serum potassium well above 4.5mEq/l.26 Table 1
summarizes changes implemented in this case based on the
absence of these risk conditions.
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